ArticleClinical breast cancer2022

A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).

Julie A Means-Powell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.